Edesa Biotech (EDSA) Enterprise Value (2013 - 2026)
Edesa Biotech (EDSA) posted Enterprise Value of -$12.1 million for Q4 2025, down 11.67% sequentially from -$10.8 million in Q3 2025, and down 670.82% YoY from $2.1 million in Q4 2024.
Edesa Biotech (EDSA) Enterprise Value (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Enterprise Value for 13 years, with the latest figure at -$12.1 million in Q4 2025.
- Quarterly Enterprise Value fell 670.82% year-over-year to -$12.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.1 million (down 670.82% YoY) and the FY2025 annual result came in at -$10.8 million, down 940.39% from the prior year.
- Enterprise Value slipped to -$12.1 million in Q4 2025 per EDSA's latest filing, from -$10.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.0 million in Q3 2024 and troughed at -$15.9 million in Q1 2022.
- A 5-year average of -$7.8 million and a median of -$7.7 million in 2021 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 80.65% in 2024, then tumbled 940.39% in 2025.
- Over 5 years, Enterprise Value stood at -$5.9 million in 2021, then sank by 40.63% to -$8.3 million in 2022, then soared by 48.4% to -$4.3 million in 2023, then soared by 63.37% to -$1.6 million in 2024, then slumped by 670.82% to -$12.1 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$12.1 million, -$10.8 million, and -$12.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Edesa Biotech | 43.15 Mn | 43.15 Mn | - | -10.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.33 Mn |
| Dec 31, 2025 | -12.05 Mn |
| Sep 30, 2025 | -10.79 Mn |
| Jun 30, 2025 | -12.36 Mn |
| Mar 31, 2025 | -13.90 Mn |
| Dec 31, 2024 | -1.56 Mn |
| Sep 30, 2024 | -1.04 Mn |
| Jun 30, 2024 | -2.04 Mn |
| Mar 31, 2024 | -2.80 Mn |
| Dec 31, 2023 | -4.27 Mn |
| Sep 30, 2023 | -5.36 Mn |
| Jun 30, 2023 | -6.46 Mn |
| Mar 31, 2023 | -7.47 Mn |
| Dec 31, 2022 | -8.27 Mn |
| Sep 30, 2022 | -7.09 Mn |
| Jun 30, 2022 | -12.81 Mn |
| Mar 31, 2022 | -15.89 Mn |
| Dec 31, 2021 | -5.88 Mn |
| Sep 30, 2021 | -7.84 Mn |
| Jun 30, 2021 | -8.05 Mn |